2996 Frovatriptan Frovatriptan is an exogenous organic compound with the formula C14H17N3O and an average molecular weight of 243.30 g/mol. It exists as a solid at room temperature. Frovatriptan belongs to the carbazoles, a subclass of indoles and derivatives within the organic compounds. This compound is recorded as being found in or released from five sources, including analgesics within healthcare, pharmaceuticals and veterinary products, household cleaning and consumer products such as other smoking requisites and non electric simulated smoking devices, and electrical and electronic equipment including television systems and electric hearing aids. The recorded exposure route is oral. Frovatriptan targets the 5-hydroxytryptamine receptor 1B (HTR1B) and 5-hydroxytryptamine receptor 1D (HTR1D). Three distinct pharmacological actions are implicated in the antimigraine effect of triptans: the stimulation of presynaptic 5-HT1D receptors, which inhibits dural inflammation and vasodilation; direct inhibition of trigeminal nuclei cell excitability through 5-HT1B/1D receptor agonism in the brainstem; and vasoconstriction of pial, cerebral, dural, or meningeal vessels resulting from vascular 5-HT1B receptor agonism. 158747-02-5 77992 C14H17N3O 243.137160 White powder. Soluble Frovatriptan is rapidly absorbed from the duodenum, but has low oral bioavailability. Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT_1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT_1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT_1B receptor agonism. In vitro, cytochrome P450 1A2 appears to be the principal enzyme involved in the metabolism of frovatriptan to several metabolites including hydroxylated frovatriptan, N-acetyl desmethyl frovatriptan, hydroxylated N-acetyl desmethyl frovatriptan and desmethyl frovatriptan, and several other minor metabolites. Desmethyl frovatriptan has lower affinity for 5-HT_1B/1D receptors compared to the parent compound. The N-acetyl desmethyl metabolite has no significant affinity for 5-HT receptors. The activity of the other metabolites is unknown. Route of Elimination: Radiolabeled compounds excreted in urine were unchanged frovatriptan, hydroxylated frovatriptan, N-acetyl desmethyl frovatriptan, hydroxylated N-acetyl desmethyl frovatriptan and desmethyl frovatriptan, together with several other minor metabolites. Less than 10% of frovatriptan was excreted in urine after an oral dose. Half Life: 26 hours No indication of carcinogenicity to humans (not listed by IARC). For the acute treatment of migraine attacks with or without aura in adults. There is no direct experience of any patient taking an overdose of Frovatriptan. The maximum single dose of frovatriptan given to male and female patients with migraine was 40 mg (16 times the clinical dose) and the maximum single dose given to healthy male subjects was 100 mg (40 times the clinical dose) without significant adverse events. As with other 5-HT1 receptor agonists, there is no specific antidote for frovatriptan. The elimination half-life of frovatriptan is 26 hours, therefore if overdose occurs, the patient should be monitored closely for at least 48 hours and be given any necessary symptomatic treatment. (L1712) 2009-07-21T20:28:08Z 2026-05-14T16:55:21Z Frovatriptan 350328 Frovatriptan DB00998 true CN[C@@H]1CCC2=C(C1)C1=C(N2)C=CC(=C1)C(N)=O C14H17N3O InChI=1S/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)/t9-/m1/s1 XPSQPHWEGNHMSK-SECBINFHSA-N 243.3043 243.137162181 Exogenous Solid 0.9 HMDB15133 CHEMBL1279 70378 <p>Samir Naik, Anthony Crasto, Narendra Joshi, Sachin Srivastava, &#8220;Amorphous frovatriptan succinate and process for the preparation thereof.&#8221; U.S. Patent US20070299123, issued December 27, 2007.</p> CHEM002317 DTXSID0023080 NS00007851 (3R)-3-(methylamino)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide 70.91 71.8382 27.552154348371012 2 2 3 14.5361936626193 10.421212164263157 1 3 1.20 -3.30 1.23e-01 g/l Organic compounds Organoheterocyclic compounds Indoles and derivatives Carbazoles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 776t3gAAAAAQAAAAAwAAAAAAAAASAAAAFAAAAIABBgBgAAAAAQMHAGAAAAAC AQYgNAAAAAIBBAYAYAAAAAICBgBgAAAAAgIGQCgAAAADBAZAKAAAAAMEBgBg AAAAAgIGQCgAAAADBAZAKAAAAAMEB0A4AAAAAwEDBkBoAAAAAwMBBkBoAAAA AwMBBkAoAAAAAwQGQGgAAAADAwEGACgAAAADBAcAaAAAAAMBAggAKAAAAAMC CwABAAECAAIDAAMEAAQFAAUGaAwGBwAGCGgMCAloDAkKaAwJC2gMCwxoDAwN aAwNDmgMDQ8gDxAgDxEoAgcCAA4IaAwKBWgMQgMAAAAGAgcGBQQDBQoJCAYF BgsMDQ4ICRcEAAAAAAAAABY= 2026-09-19T04:00:40Z